Want to see AU:CUV full AI Analyst Report?
Top Page
Clinuvel Pharmaceuticals
(Sydney:CUV)
Select Model
Select Model
Rating:72Outperform
Price Target:
AU$8.00
▼(-24.53% Downside)
Action:Reiterated
Date:09/26/26
The score is supported primarily by strong financial quality (profitability, cash generation, and an exceptionally conservative balance sheet). This is partially offset by weak technical momentum (below key moving averages with negative MACD) and only modest dividend support, despite a reasonable P/E valuation.
Positive Factors
Conservative balance sheet
Extremely low leverage materially reduces financial risk and preserves flexibility for ongoing operations, research, and commercialization. A steadily expanding equity base also provides resilience if profitability moderates, making the company less dependent on external financing or refinancing conditions.
Negative Factors
Recent revenue contraction
The return to negative revenue growth interrupts the company’s prior expansion trend and raises questions about the durability of demand or commercial execution. If the contraction persists, it could reduce operating leverage, constrain reinvestment capacity, and weaken the foundation for future earnings growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Extremely low leverage materially reduces financial risk and preserves flexibility for ongoing operations, research, and commercialization. A steadily expanding equity base also provides resilience if profitability moderates, making the company less dependent on external financing or refinancing conditions.
Read all positive factors
Clinuvel Pharmaceuticals (CUV) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$359.47M
Dividend Yield0.7%
Average Volume (3M)153.76K
Price to Earnings (P/E)10.5
Beta (1Y)0.56
Revenue Growth-1.05%
EPS Growth-6.74%
CountryAU
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.68
Shares Outstanding50,487,125
10 Day Avg. Volume208,419
30 Day Avg. Volume153,763
Financial Highlights & Ratios
PEG Ratio-2.72
Price to Book (P/B)1.88
Price to Sales (P/S)5.45
P/FCF Ratio14.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$16.35Price Target Upside54.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.67
Revenue Forecast (FY)AU$93.52M
Clinuvel Pharmaceuticals Business Overview & Revenue Model
Company Description
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, t...
How the Company Makes Money
Clinuvel makes money primarily by selling its marketed drug, SCENESSE (afamelanotide), in regions where it is approved for use in EPP. Revenue is generated through commercialization of the product (i.e., product sales/receipts from supplying SCENE...
Clinuvel Pharmaceuticals Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Feb 23, 2027
Earnings Call Sentiment Positive
The call conveys a generally positive outlook driven by modest revenue growth, record first-half sales, strong cash reserves and sustained profitability while management deliberately invests in in-house R&D, clinical and manufacturing capabilities. Those positives are tempered by materially higher operating expenses across personnel, R&D and corporate areas, a non-cash FX translation loss, and timing/uncertainty around regulatory filings (CUV107 completion required before submission) and the NASDAQ ADR uplift. On balance, the company emphasizes that expense increases are strategic investments supported by a strong balance sheet and cash runway.Positive Updates
Revenue Growth and Record First-Half Sales
Sales revenue increased 4% year-on-year to just under $37 million, marking the company's highest-ever first-half sales and continuing a steady growth pattern.
Negative Updates
Overall Expense Growth
Total expenses increased 22% for the period, driven by the company’s expansion initiatives and higher operating activity, resulting in lower net profit relative to prior periods.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth and Record First-Half Sales
Sales revenue increased 4% year-on-year to just under $37 million, marking the company's highest-ever first-half sales and continuing a steady growth pattern.
Read all positive updates
Company Guidance
Guidance from the call was that CLINUVEL will continue a controlled expansion while tightly managing costs, with full‑year operating expense guidance of about A$55–58m (ex‑capex); H1 sales rose 4% YoY to just under A$37m (the highest H1 on record), interest income was A$5.3m (up 14%), cash increased by A$9m to A$233m, net assets rose A$8.2m to ~A$250m, the company remains debt‑free for a 21st year and has delivered its 20th consecutive profit. Management flagged expense drivers (total expenses +22%: personnel +16%, commercial distribution +42%, finance/legal +47%, other R&D +191%), lower non‑cash and share‑based charges (share plan now 1‑year), term deposits average ~300 days at ~4.5% yield, revenue split ~53% U.S./47% RoW, <5% U.S. patients on Medicaid, and near‑term catalysts include CUV105 topline in H2 2026, start of CUV107, peptide preclinical data H2 2026 and the ADR/NASDAQ uplift pending SEC responses.Clinuvel Pharmaceuticals Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
84
Very Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 94.02M | 95.02M | 88.18M | 78.32M | 65.72M |
| Gross Profit | 78.21M | 79.14M | 80.45M | 50.59M | 46.62M |
| EBITDA | 41.52M | 57.20M | 56.28M | 46.37M | 35.08M |
| Net Income | 33.92M | 36.17M | 35.64M | 30.60M | 20.88M |
Balance Sheet | |||||
| Total Assets | 296.15M | 271.75M | 231.12M | 194.52M | 144.81M |
| Cash, Cash Equivalents and Short-Term Investments | 252.06M | 224.11M | 183.87M | 156.81M | 121.51M |
| Total Debt | 1.94M | 528.53K | 879.78K | 999.87K | 1.26M |
| Total Liabilities | 23.27M | 30.94M | 28.11M | 29.89M | 19.25M |
| Stockholders Equity | 272.88M | 240.81M | 203.01M | 164.63M | 125.56M |
Cash Flow | |||||
| Free Cash Flow | 35.31M | 40.80M | 31.48M | 35.88M | 39.44M |
| Operating Cash Flow | 36.91M | 41.10M | 37.05M | 36.91M | 39.87M |
| Investing Cash Flow | -39.12M | -47.72M | -29.03M | -1.03M | -434.44K |
| Financing Cash Flow | -2.75M | -2.94M | -3.57M | -2.24M | -1.50M |
Clinuvel Pharmaceuticals Technical Analysis
Negative
10.60
Price Trends
8.42
Negative
9.07
Negative
9.56
Negative
Market Momentum
-0.33
Positive
31.19
Neutral
37.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CUV, the sentiment is Negative. The current price of 10.6 is above the 20-day moving average (MA) of 7.84, above the 50-day MA of 8.42, and above the 200-day MA of 9.56, indicating a bearish trend. The MACD of -0.33 indicates Positive momentum. The RSI at 31.19 is Neutral, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CUV.
Clinuvel Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$359.47M | 10.47 | 13.00% | 0.70% | -1.05% | -6.74% | |
70 Outperform | AU$83.31M | 22.36 | 46.74% | ― | 29.68% | 1520.00% | |
52 Neutral | AU$1.75B | -30.12 | -10.31% | ― | ― | 39.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$6.12M | -7.14 | -45.29% | 9.09% | 290.25% | 92.05% | |
44 Neutral | AU$33.14M | -0.37 | -118.74% | ― | 499.47% | 31.20% | |
43 Neutral | AU$223.08M | -27.19 | -42.35% | ― | 145.32% | 25.75% |
* Healthcare Sector Average
AU:CUV
Clinuvel Pharmaceuticals
7.12
-4.21
-37.16%
AU:ACR
Acrux
0.01
>-0.01
-23.08%
AU:SPL
Starpharma Holdings Limited
0.47
0.13
40.48%
AU:PYC
PYC Therapeutics Limited
1.78
0.59
49.45%
AU:BOT
Botanix Pharmaceuticals Limited
0.01
-0.13
-91.43%
AU:BIO
Biome Australia Ltd
0.36
-0.11
-22.58%
Clinuvel Pharmaceuticals Corporate Events
Clinuvel Pharmaceuticals Reports Expiry of 61,272 Performance Rights
Oct 5, 2026
Clinuvel Pharmaceuticals has reported the cessation of 61,272 performance rights, identified under ASX security code CUVAK, following their expiry without exercise or conversion on September 30, 2026. The notification, lodged as an Appendix 3H, ou...
Clinuvel Seeks ASX Quotation for Additional Ordinary Shares
Oct 5, 2026
Clinuvel Pharmaceuticals has applied for quotation of 59,228 new ordinary fully paid shares on the ASX, with an issue date of September 30, 2026. The additional securities, arising from exercised options or converted instruments, modestly expand t...
Clinuvel urges stability ahead of AGM as board warns against potential spill
Oct 1, 2026
Clinuvel Pharmaceuticals has called its 2026 Annual General Meeting for 6 November in Melbourne, where shareholders will vote on the adoption of the latest remuneration report, the re-election of two non-executive directors and, if triggered, a co...
Clinuvel Shows Sustained Vitiligo Repigmentation with SCENESSE Combo Therapy
Oct 1, 2026
Clinuvel Pharmaceuticals reported new clinical cases from its CUV105 vitiligo trial showing a positive response to SCENESSE (afamelanotide) used with adjunct narrowband UVB phototherapy. The data, presented at the European Academy of Dermatology a...
Clinuvel Unveils ZEROKIN Device to Target Growing Self-Injection Market
Sep 7, 2026
Clinuvel Pharmaceuticals has completed development of ZEROKIN, a proprietary single-use subcutaneous administration device designed for controlled-release formulations, initially targeting melanocortin peptides developed at its Singapore RD hub. P...
Vanguard Drops Below Substantial Holder Threshold in Clinuvel Pharmaceuticals
Sep 1, 2026
Vanguard Group, including its controlled entities such as Vanguard Investments Australia Ltd., has notified Clinuvel Pharmaceuticals that it has ceased to be a substantial holder in the company. The disclosure, lodged under Australia’s Corpo...
Clinuvel Weighs Nasdaq-Only Listing as Headquarters Shift to U.S.
Aug 27, 2026
Clinuvel Pharmaceuticals’ board is evaluating a restructuring that would shift the group’s holding company offshore, list all ordinary shares on Nasdaq and delist from the Australian Securities Exchange and Frankfurt’s Börse...
Clinuvel Flags Key Risks as It Builds U.S.-Led Expansion
Aug 27, 2026
Clinuvel Pharmaceuticals has outlined its risk landscape as it prepares for expanded operations, including a stated focus on the U.S. market supported by its existing global foundation. The group highlights exposure to competition for its lead pro...
Clinuvel Confirms ASX Governance Compliance With 2026 Appendix 4G Filing
Aug 27, 2026
Clinuvel Pharmaceuticals has lodged its Appendix 4G with the ASX for the financial year ended 30 June 2026, confirming that its corporate governance statement is current as at 27 August 2026 and available on its website. The filing outlines that C...
Clinuvel Affirms ASX Governance Compliance and Highlights Diversity Gains
Aug 27, 2026
Clinuvel Pharmaceuticals has released its corporate governance statement for the year to 30 June 2026, confirming full compliance with the Australian Securities Exchange Corporate Governance Council’s 4th edition principles and recommendatio...
Clinuvel Declares AUD 0.05 Dividend for FY2026
Aug 27, 2026
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company listed on the ASX under the code CUV, with ordinary fully paid shares as its primary security. The company operates in the pharmaceuticals industry, focusing on the develo...
Clinuvel Leverages Decade of Profits to Fund U.S. Expansion Despite Flat FY2026 Revenue
Aug 27, 2026
Clinuvel Pharmaceuticals reported its tenth consecutive annual profit for the year ended 30 June 2026, supported by record SCENESSE treatment volumes and steady operating expenses. Revenue from ordinary activities slipped 1% to A$94.0 million, whi...
Clinuvel Sets Investor Webinar to Unveil 2026 Annual Results
Aug 20, 2026
Clinuvel Pharmaceuticals will release its annual financial results for the year ended 30 June 2026 on 27 August, accompanied by an investor and analyst webinar later that day. The online event, scheduled for 18:00 to 18:30 AEST, will allow partici...
Clinuvel Advances VLRX-L Controlled-Release Injectable Peptide Platform
Aug 11, 2026
Clinuvel Pharmaceuticals has reported progress on its VLRX-L controlled-release injectable liquid peptide platform, narrowing four preclinical formulations down to a lead candidate with a superior release profile. The optimized liquid formulation ...
Clinuvel steps up vitiligo push as SCENESSE data and North American rollout near
Jul 29, 2026
Clinuvel Pharmaceuticals has provided a commercial update on the emerging vitiligo treatment landscape, contrasting the longstanding narrowband UVB standard of care and newer topical and systemic JAK inhibitors with its SCENESSE therapy. The compa...
Clinuvel maps SCENESSE’s path in vitiligo with new Phase III trial
Jul 27, 2026
Clinuvel Pharmaceuticals has outlined the clinical and regulatory pathway to develop SCENESSE with narrowband UVB phototherapy as a treatment for vitiligo in patients with darker skin types. The company is completing its first late-stage vitiligo ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.